Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

HPV vaccination rates in New Mexico and future directions for promoting the HPV vaccine among young adults.

Sreeya Kairamkonda, Prajakta Adsul Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22540

e22540 Background: The Human Papillomavirus (HPV) is the most common sexually transmitted infection in the U.S. and is att...

Global context modeling with vision transformers for MRI-based classification of brain tumors.

Ramya Elangovan, Gowrishankar Palaniswamy, Elangovan Krishnan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14003

e14003 Background: Brain tumors represent a heterogeneous group of neoplasms with widely variable prognosis and treatment...

Real-world effectiveness of disitamab vedotin plus PD-1 inhibitor versus platinum-based chemotherapy as postoperative adjuvant therapy in high-risk upper tract urothelial carcinoma: A comparative study.

Yudong Cao, Mingjian Ruan, Shuo Wang et al. Jun 01, 2026 pp. 4611-4611 10.1200/jco.2026.44.16_suppl.4611

4611 Background: Currently, gemcitabine–platinum combination chemotherapy represents the standard adjuvant regimen followi...

Advancing equity in clinical trials through decentralized methodology: A national position statement.

Sabe S. Sabesan, Francis Hinds, Anne Woolett et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23022

e23022 Background: Regional/Rural and socially disadvantaged populations continue to face persistent barriers to clinical...

Triple M syndrome following immune checkpoint inhibitors: Clinical features and mortality drivers of a severe irAE.

Tessa Lavorgna, Jose Noy, Chinmay Jani et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23431

e23431 Background: Triple M overlap syndrome (TMOS) is a rare but lethal immune related adverse event (irAE) characterized...

Comparative real-world outcomes of tarlatamab and lurbinectedin in relapsed extensive-stage small cell lung cancer.

Daniyal Aziz Khan, Haris Sohail, Farzeen Fatma Syed et al. Jun 01, 2026 pp. 8100-8100 10.1200/jco.2026.44.16_suppl.8100

8100 Background: Extensive stage small cell lung cancer is an aggressive malignancy with rapid progression and poor surviv...

Characterizing spatial tumor architecture and ECM recapitulation using an EO771 syngeneic TNBC model.

Libby A. Boykin, Khidr Kishan K. Budhwani, Brahma Mubarak K. Budhwani et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13133

e13133 Background: Triple-negative breast cancer (TNBC) remains an aggressive malignancy with limited therapeutic options...

Tumor CTR1 expression and longitudinal serum copper assessment in breast cancer patients treated in the neoadjuvant setting.

Christos N. Papageorgiou, Vinit Shanbhag, Linda T. Vahdat Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12629

e12629 Background: Copper is an essential nutrient required for energy production, antioxidant defense, and connective tis...

Prevalence and prognostic value of Claudin 18.2 expression in pancreatic ductal adenocarcinoma.

Kevin Zi Ming Lim, Louise Laurberg Klarskov, Leigh Carter et al. Jun 01, 2026 pp. 4188-4188 10.1200/jco.2026.44.16_suppl.4188

4188 Background: Although Claudin18.2 expression (CLDN18.2) has been investigated in pancreatic ductal adenocarcinoma (PDA...

A systematic review and meta-analysis evaluating role of AI-, ML-, and DL-based models for predicting recurrence risk after curative surgical resection of colorectal cancer liver metastases.

Sheilabi Seeburun, Kesar Prajapati, Priyaranjan Kata et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15517

e15517 Background: Recurrence following curative-intent hepatic resection for colorectal cancer liver metastases (CRLM) re...

Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study.

Linda R. Mileshkin, Stephanie Gaillard, Robin Guo et al. Jun 01, 2026 pp. 5515-5515 10.1200/jco.2026.44.16_suppl.5515

5515 Background: B7-H4, a transmembrane glycoprotein that negatively regulates T cells, is highly expressed in EC and OC....

Detection of mutational signatures in advanced cancer patients using clinical-grade specimens.

Samantha Rueckeis, Ryan Hausler, Iskander Said et al. Jun 01, 2026 pp. 3137-3137 10.1200/jco.2026.44.16_suppl.3137

3137 Background: The underlying extrinsic and/or intrinsic mutational processes underlying tumor development lead to genom...

Effect of treatment delay on outcomes with adjuvant chemotherapy vs chemoradiotherapy in R1-resected biliary tract cancers.

Muhammet Ozer, Suleyman Yasin Goksu, Brandon Edward Rose et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16267

e16267 Background: R1 margins after biliary tract cancer (BTC) resection are associated with high recurrence risk. The rol...

A phase II study to evaluate the safety and efficacy of BB-1701 in combination with sintilimab in patients with HER2 expression or mutation in locally advanced/metastatic breast cancer or NSCLC.

Anwen Xiong, Jin Yang, Jing Zhang et al. Jun 01, 2026 pp. 2632-2632 10.1200/jco.2026.44.16_suppl.2632

2632 Background: BB-1701, a HER2-targeting antibody-drug conjugate (ADC) containing eribulin, has demonstrated promising a...

A novel bispecific RDC+ADC theranostic approach to overcome trastuzumab deruxtecan resistance and tumor heterogeneity.

Hua Hao, Yi Zhao, Jie Gao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15150

e15150 Background: Resistance to single-antigen HER2-targeted ADCs, such as trastuzumab deruxtecan and trastuzumab emtansi...

Survival outcomes of human epidermal growth factor receptor 2 (HER2)–amplified and HER2-mutated left-sided colorectal cancer (CRC) patients treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).

Yu Jen Alexander Jan, Kieran Sweeney, Andrew Elliott et al. Jun 01, 2026 pp. 3543-3543 10.1200/jco.2026.44.16_suppl.3543

3543 Background: Current guidelines support the use of anti-EGFR mAbs in left-sided CRCs without mutations in...

Diagnostic accuracy of urine-based HPV testing for cervical neoplasia and cancer: A landmark systematic review and meta-analysis.

Bhaskar Kambhampati, Tarun Kumar Suvvari, Sridhar V. N. S. Kocharlakota et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17506

e17506 Background: Urine-based human papillomavirus (HPV) testing offers a non-invasive screening alternative that could i...

Teliso-V monotherapy and EGFR-TKI combinations in c-Met–over-expressing NSCLC: A systematic review and meta-analysis.

Fatima Ali, Ahmed M. Kedwany, Amna Khalid et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20714

e20714 Background: c-Met protein over-expression is frequent in non-small cell lung cancer (NSCLC) and is linked to poor p...

Heart failure in hospitalizations for hematologic malignancies versus solid tumors: National burden and inpatient outcomes, 2018-2022.

Dylan Lee, Ramaditya Srinivasmurthy, Riccesha Hattin et al. Jun 01, 2026 pp. 11074-11074 10.1200/jco.2026.44.16_suppl.11074

11074 Background: Heart failure (HF) is a common and morbid comorbidity in oncology. Whether HF burden and prognosis diffe...

Recovery with residual disparities: Real-world patterns of platinum chemotherapy use after the 2023 drug shortage.

Omer Sayed Ashruf, Zara Orozco, Sydney Cooper et al. Jun 01, 2026 pp. 1562-1562 10.1200/jco.2026.44.16_suppl.1562

1562 Background: The 2023 national shortages of cisplatin and carboplatin disrupted standard cancer treatment across multi...

Sleep disorder diagnosis prevalence among adult cancer patients.

Chloe M. Hery, Kian Xie, Brian Finn et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24113

e24113 Background: Sleep is commonly impacted by cancer diagnosis and treatment. Poor sleep is consistently reported to be...

Clinico-transcriptomic risk stratification to guide abiraterone treatment intensification in high-risk prostate cancer: A combined analysis of NRG/RTOG 9202, 9413, 9902, and 0521.

Krishnan R. Patel, Eli Rosenbaum, Marla Johnson et al. Jun 01, 2026 pp. 5000-5000 10.1200/jco.2026.44.16_suppl.5000

5000 Background: Outcomes for some patients with ≥high-risk localized prostate cancer (HR-PCa) who receive radiati...

Neoadjuvant chemoimmunotherapy before chemoradiation vs chemoradiation alone for stage IIB-IIIC1 carcinoma of the cervix: A phase II open-label randomized controlled trial (NeoCHIMERA).

Praveen Kumar Marimuthu, Neenu Oliver John, Vinitha Tony et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5631

TPS5631 Background: Locally advanced cervical cancer (FIGO 2018 stages IIB–IIIC1) remains a major cause of cancer-related...

Oncologic safety and patient-reported outcomes of sentinel lymph node biopsy omission in early breast cancer: A meta-analysis of randomized controlled trials.

Ursula Medeiros Araujo de Matos, Anderson Matheus Pereira da Silva, Patrick Meldola et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12618

e12618 Background: Sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection for axillary staging in c...

Race-associated clinicogenomic predictors in non-small cell lung cancer treated with immune checkpoint inhibitors.

Nirosha Perera King, Rochelle Fayngor, Lingzhi Hong et al. Jun 01, 2026 pp. 8557-8557 10.1200/jco.2026.44.16_suppl.8557

8557 Background: PD-L1 low and STK11 mutation associate with immune checkpoint inhibitor (ICI) resistance in non-small cel...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page